129 related articles for article (PubMed ID: 32958446)
1. Novel treatment of upper tract urothelial carcinoma in situ with docetaxel in BCG refractory patients.
Katims AB; Tam AW; Rosen DC; Zampini AM; Atallah W; Mehrazin R; Gupta M
Urol Oncol; 2021 Apr; 39(4):234.e9-234.e13. PubMed ID: 32958446
[TBL] [Abstract][Full Text] [Related]
2. Outcomes of intrarenal Bacillus Calmette-Guérin/interferon-α2B for biopsy-proven upper-tract carcinoma in situ.
Shapiro EY; Lipsky MJ; Cha DY; McKiernan JM; Benson MC; Gupta M
J Endourol; 2012 Dec; 26(12):1645-50. PubMed ID: 22834939
[TBL] [Abstract][Full Text] [Related]
3. Long-term experience with bacillus Calmette-Guerin therapy of upper urinary tract transitional cell carcinoma in patients not eligible for surgery.
Thalmann GN; Markwalder R; Walter B; Studer UE
J Urol; 2002 Oct; 168(4 Pt 1):1381-5. PubMed ID: 12352398
[TBL] [Abstract][Full Text] [Related]
4. Management of primary upper urinary tract carcinoma in situ diagnosed by ureteroscopic biopsy: Is bacillus Calmette-Guerin an alternative to nephroureterectomy?
Territo A; Fontanet S; Meneghetti I; Gallioli A; Sanguedolce F; Rodriguez-Faba Ó; Gaya JM; Palou J; Huguet J; Breda A
Actas Urol Esp (Engl Ed); 2023 May; 47(4):221-228. PubMed ID: 36379260
[TBL] [Abstract][Full Text] [Related]
5. Sequential endoluminal gemcitabine and docetaxel vs. Bacillus Calmette-Guérin for the treatment of upper tract carcinoma in situ.
McElree IM; Mott SL; Hougen HY; Packiam VT; O'Donnell MA; Steinberg RL
Urol Oncol; 2024 Jul; 42(7):221.e9-221.e16. PubMed ID: 38609747
[TBL] [Abstract][Full Text] [Related]
6. Salvage topical therapy for upper tract urothelial carcinoma.
Balasubramanian A; Metcalfe MJ; Wagenheim G; Xiao L; Papadopoulos J; Navai N; Davis JW; Karam JA; Kamat AM; Wood CG; Dinney CP; Matin SF
World J Urol; 2018 Dec; 36(12):2027-2034. PubMed ID: 29804202
[TBL] [Abstract][Full Text] [Related]
7. Upper urinary tract instillations in the treatment of urothelial carcinomas: a review of technical constraints and outcomes.
Audenet F; Traxer O; Bensalah K; Rouprêt M
World J Urol; 2013 Feb; 31(1):45-52. PubMed ID: 23007718
[TBL] [Abstract][Full Text] [Related]
8. Bacillus Calmette-Guérin perfusion therapy for the treatment of transitional cell carcinoma in situ of the upper urinary tract.
Nonomura N; Ono Y; Nozawa M; Fukui T; Harada Y; Nishimura K; Takaha N; Takahara S; Okuyama A
Eur Urol; 2000 Dec; 38(6):701-4;discussion 705. PubMed ID: 11111187
[TBL] [Abstract][Full Text] [Related]
9. Bacillus Calmette-Guérin failure in patients with non-muscle-invasive urothelial carcinoma of the bladder may be due to the urologist's failure to detect urothelial carcinoma of the upper urinary tract and urethra.
Giannarini G; Birkhäuser FD; Recker F; Thalmann GN; Studer UE
Eur Urol; 2014 Apr; 65(4):825-31. PubMed ID: 24144432
[TBL] [Abstract][Full Text] [Related]
10. Impact of bacillus Calmette-Guérin therapy of upper urinary tract carcinoma in situ: comparison of oncological outcomes with radical nephroureterectomy.
Horiguchi H; Yoneyama T; Hatakeyama S; Tokui N; Sato T; Fujita N; Yamamoto H; Tobisawa Y; Yoneyama T; Hashimoto Y; Koie T; Yoshikawa K; Narita S; Kawaguchi T; Ohyama C
Med Oncol; 2018 Feb; 35(4):41. PubMed ID: 29480348
[TBL] [Abstract][Full Text] [Related]
11. The Expanded Use of Percutaneous Resection for Upper Tract Urothelial Carcinoma: A 30-Year Comprehensive Experience.
Motamedinia P; Keheila M; Leavitt DA; Rastinehad AR; Okeke Z; Smith AD
J Endourol; 2016 Mar; 30(3):262-7. PubMed ID: 26630130
[TBL] [Abstract][Full Text] [Related]
12. Setting a new standard for topical therapy of upper-tract transitional-cell carcinoma: BCG and interferon-alpha2B.
Katz MH; Lee MW; Gupta M
J Endourol; 2007 Apr; 21(4):374-7; discussion 377. PubMed ID: 17451325
[TBL] [Abstract][Full Text] [Related]
13. [Intrarenal bacillus Calmette-Guerin therapy for carcinoma in situ of the upper urinary tract].
Okubo K; Ishitoya S; Maeda H; Suzuki Y; Arai Y
Nihon Hinyokika Gakkai Zasshi; 1997 Mar; 88(3):386-90. PubMed ID: 9125861
[TBL] [Abstract][Full Text] [Related]
14. Endocavitary treatment for upper tract urothelial carcinoma: A meta-analysis of the current literature.
Foerster B; D'Andrea D; Abufaraj M; Broenimann S; Karakiewicz PI; Rouprêt M; Gontero P; Lerner SP; Shariat SF; Soria F
Urol Oncol; 2019 Jul; 37(7):430-436. PubMed ID: 30846387
[TBL] [Abstract][Full Text] [Related]
15. Adjuvant topical treatment of upper urinary tract urothelial tumours.
O'Donoghue JP; Crew JP
BJU Int; 2004 Sep; 94(4):483-5. PubMed ID: 15329096
[No Abstract] [Full Text] [Related]
16. Ureteroscopic and percutaneous management of upper tract urothelial carcinoma (UTUC): systematic review.
Cutress ML; Stewart GD; Zakikhani P; Phipps S; Thomas BG; Tolley DA
BJU Int; 2012 Sep; 110(5):614-28. PubMed ID: 22471401
[TBL] [Abstract][Full Text] [Related]
17. Sequential endoluminal gemcitabine and docetaxel for the treatment of clinically non-invasive high-grade upper tract urothelial carcinoma.
McElree IM; Belzer A; Mott SL; Packiam VT; O'Donnell MA; Steinberg RL
Urol Oncol; 2024 Jan; 42(1):20.e9-20.e15. PubMed ID: 37805338
[TBL] [Abstract][Full Text] [Related]
18. Induction and Maintenance Adjuvant Mitomycin C Topical Therapy for Upper Tract Urothelial Carcinoma: Tolerability and Intermediate Term Outcomes.
Metcalfe M; Wagenheim G; Xiao L; Papadopoulos J; Navai N; Davis JW; Karam JA; Kamat AM; Wood CG; Dinney CP; Matin SF
J Endourol; 2017 Sep; 31(9):946-953. PubMed ID: 28731777
[TBL] [Abstract][Full Text] [Related]
19. Clinical outcome of bacillus Calmette-Guérin perfusion therapy for carcinoma in situ of the upper urinary tract.
Miyake H; Eto H; Hara S; Okada H; Kamidono S; Hara I
Int J Urol; 2002 Dec; 9(12):677-80. PubMed ID: 12492951
[TBL] [Abstract][Full Text] [Related]
20. Long-term outcome of upper urinary tract carcinoma in situ: effectiveness of nephroureterectomy versus bacillus Calmette-Guérin therapy.
Kojima Y; Tozawa K; Kawai N; Sasaki S; Hayashi Y; Kohri K
Int J Urol; 2006 Apr; 13(4):340-4. PubMed ID: 16734847
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
